MedTrace Logo

The Efficacy of Bakuchiol in Treating PIH

NCT06833996 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-02-19

No results posted yet for this study

Summary

Post-inflammatory hyperpigmentation (PIH) is an acquired hyper melanosis that occurs after cutaneous inflammation or injury frequently affecting darker skinned individuals. Bakuchiol is derived from plants and has inhibitory effects on melanin synthesis, which makes it a promising therapeutic intervention in the management of PIH. This study aims to evaluate the efficacy of bakuchiol in treating post inflammatory hyperpigmentation using the investigators previously validated model in comparison to acne induced PIH.

Conditions

  • Post Inflammatory Hyperpigmentation

Interventions

DRUG

Bakuchiol

Apply bakuchiol cream twice daily to a select acne induced and TCA induced PIH spot for a total of 28 days

DRUG

Vehicle

Apply vehicle cream twice daily to a select acne induced and TCA induced PIH spot for a total of 28 days

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Principal Investigators

  • Iltefat Hamzavi, MD · Henry Ford Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-22
Primary Completion
2018-05-23
Completion
2019-05-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06833996 on ClinicalTrials.gov